U.S. Department of Health & Human Services
National Institutes of Health
NCATS
Return Home
Inxight
Drugs
Search Substances
Home
Browse Drugs
US Approved Drugs
Marketed Drugs
Investigational Drugs
All Substances
Search
Structure Search
Sequence Search
Downloads
About
Search Substances
CATRIDECACOG
NU23Q531G1
US Approved Rx (2013)
First approved in 2013
General
Record Details
Names
15
Classification
6
Identifiers
13
Subunits
2
Glycosylation
2
Active Moiety
1
Characteristic Attributes
2
CATRIDECACOG
NU23Q531G1
US Approved Rx (2013)
First approved in 2013
General
Approval Year
2013
596
Record Details
Substance Class
Protein
Protein Sub Type
Sequence Type
COMPLETE
Record UNII
NU23Q531G1
Record Status
Validated (UNII)
Record Version
21
20
19
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
Names
15
Show
5
20
100
All
entries
Name
Type
Language
Name
Type
Language
CATRIDECACOG
Official Name
English
HUMAN RECOMBINANT FACTOR XIII SUBUNIT A DIMER
Common Name
English
COAGULATION FACTOR XIII A SUBUNIT (RECOMBINANT)
Common Name
English
COAGULATION FACTOR XIII A-SUBUNIT RECOMBINANT
Common Name
English
RECOMBINANT COAGULATION FACTOR XIII A-SUBUNIT
Common Name
English
Showing 1 to 5 of 15 entries
Previous
1
2
3
Next
Classification
6
Show
5
20
100
All
entries
Classification Tree
Code System
Code
Classification Tree
Code System
Code
Blood coagulation factors
VATC
ANTIHEMORRHAGICS
VITAMIN K AND OTHER HEMOSTATICS
Blood coagulation factors
catridecacog
WHO-VATC
QB02BD11
Blood coagulation factors
ATC
BLOOD AND BLOOD FORMING ORGANS
ANTIHEMORRHAGICS
VITAMIN K AND OTHER HEMOSTATICS
Blood coagulation factors
catridecacog
WHO-ATC
B02BD11
Designated/Approved
ORPHAN DRUG
Designated/Approved
Prophylaxis of bleeding associated with congential factor XIII deficiency
FDA ORPHAN DRUG
174803
BLOOD COAGULATION DISORDERS
EMA EPAR
DISEASES
BLOOD AND LYMPHATIC DISEASES
HEMATOLOGIC DISEASES
BLOOD COAGULATION DISORDERS
BLOOD COAGULATION DISORDERS, INHERITED
EMA ASSESSMENT REPORTS
NOVOTHIRTEEN (AUTHORIZED:CONGENITAL FACTOR XIII A-SUBUNIT DEFICIENCY)
Designated/Withdrawn
ORPHAN DRUG
Designated/Withdrawn
Treatment of congenital factor XIII deficiency.
FDA ORPHAN DRUG
73993
Showing 1 to 5 of 6 entries
Previous
1
2
Next
Identifiers
13
Show
5
20
100
All
entries
Code System
Code
Type
Description
Code System
Code
Type
Description
WIKIPEDIA
Catridecacog
PRIMARY
CAS
606138-08-3
PRIMARY
ChEMBL
CHEMBL2108282
PRIMARY
FDA UNII
NU23Q531G1
PRIMARY
RXCUI
1488293
PRIMARY
Showing 1 to 5 of 13 entries
Previous
1
2
3
Next
Subunits
2
Subunit 0
>SUBUNIT_0
Subunit 1
>SUBUNIT_1
Glycosylation
2
Glycosylation Type
YEAST
Show
5
20
100
All
entries
Glycosylation Link Type
Site
Glycosylation Link Type
Site
N
1_613
N
2_613
Showing 1 to 2 of 2 entries
Previous
1
Next
Active Moiety
1
Show
5
20
100
All
entries
Related Record
Type
Details
Related Record
Type
Details
NU23Q531G1
CATRIDECACOG
ACTIVE MOIETY
Showing 1 to 1 of 1 entries
Previous
1
Next
Characteristic Attributes
2
Show
5
20
100
All
entries
Name
Property Type
Amount
Referenced Substance
Defining
Parameters
References
Name
Property Type
Amount
Referenced Substance
Defining
Parameters
References
Molecular Formula
CHEMICAL
ESTIMATED
C7412H11386N2026O2220S56
MOL_WEIGHT:NUMBER AVERAGE(CALCULATED)
CHEMICAL
NUMBER AVERAGE 332000 Da (average)
Showing 1 to 2 of 2 entries
Previous
1
Next
